Bladder Cancer: Narrowing the Gap Between Evidence and Practice-Reference-Cited by-同舟云学术

Bladder Cancer: Narrowing the Gap Between Evidence and Practice

Published:2009-12-01 Issue:34 Volume:27 Page:5680-5684
ISSN:0732-183X
Container-title:Journal of Clinical Oncology
language:en
Short-container-title:JCO

Author:

Hussain Maha H.A.¹,Wood David P.¹,Bajorin Dean F.²,Bochner Bernard H.²,Dreicer Robert³,Lamm Donald L.⁴,O'Donnell Michael A.⁵,Siefker-Radtke Arlene O.⁶,Theodorescu Dan⁷,Dinney Colin P.⁶

Affiliation:

1. University of Michigan Comprehensive Cancer Center, Ann Arbor, MI

2. Memorial-Sloan Kettering Cancer Center, New York, NY

3. The Cleveland Clinic Foundation, Cleveland, OH

4. BCG Oncology, Phoenix, AZ

5. University of Iowa, Iowa City, IA

6. The University of Texas M. D. Anderson Cancer Center, Houston, TX

7. University of Virginia, Charlottesville, VA

Publisher

American Society of Clinical Oncology (ASCO)

Subject

Cancer Research,Oncology

Link

http://ascopubs.org/doi/pdfdirect/10.1200/JCO.2009.23.6901

Reference55 articles.

1. Integrating Perioperative Chemotherapy into the Treatment of Muscle-Invasive Bladder Cancer: Strategy Versus Reality

2. Superficial Bladder Cancer: Progression and Recurrence

3. The Treated Natural History of High Risk Superficial Bladder Cancer: 15-year Outcome

4. A SINGLE IMMEDIATE POSTOPERATIVE INSTILLATION OF CHEMOTHERAPY DECREASES THE RISK OF RECURRENCE IN PATIENTS WITH STAGE Ta T1 BLADDER CANCER: A META-ANALYSIS OF PUBLISHED RESULTS OF RANDOMIZED CLINICAL TRIALS

5. Perioperative Single Dose Instillation of Epirubicin or Interferon-α After Transurethral Resection for The Prophylaxis of Primary Superficial Bladder Cancer Recurrence: A Prospective Randomized Multicenter Study—Finnbladder III Long-Term Results

Cited by 54 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy and safety of tislelizumab plus bacillus-calmette guérin with or without chemotherapy as a bladder-sparing treatment for high-risk non-muscle-invasive bladder urothelial cancer: a real-world study;Discover Oncology;2024-07-08

2. Pembrolizumab monotherapy for high-risk non-muscle-invasive bladder cancer without carcinoma in situ and unresponsive to BCG (KEYNOTE-057): a single-arm, multicentre, phase 2 trial;The Lancet Oncology;2024-06

3. Integrative analysis of the bladder cancer from a cell cycle NCAM1 perspective at both single cell and bulk resolution;Environmental Toxicology;2024-04-06

4. Gemcitabine as first-line therapy for high-grade non-muscle invasive bladder cancer: results from a tertiary center in the contemporary BCG-shortage era;Translational Andrology and Urology;2023-06

5. Application of nanotechnology in bladder cancer diagnosis and therapeutic drug delivery;Journal of Materials Chemistry B;2023